Loading ...
Significant differences in total cf - DNAleadingto a significantly decreased fetal fraction
another draw ... 11 weeksresultedin Low Fetal Fraction
cmurray87(passive) Created byinsufficient DNA low fetal fraction
the so - called congestive heart failurecauseslow ejection fraction
increased levels of serum total DNA in patients with active SLE [ 28 , 29could leadto a low fetal fraction
niptresultsfetal fraction
active coronary artery disease , long - standing hypertension , viral infections and valvular disease(passive) may be caused byLow Ejection fraction
bright white lightcausesa low metarhodopsin fraction
infectious diseasecausinglow ejection fraction
so that tools Are hard emphasizeto createthe low fraction
valence quarkscontributeunexpectedly low fraction
from poor sample management ( sample collection procedures , delays in plasma extraction ) or biological factors such as obesityresultfrom poor sample management ( sample collection procedures , delays in plasma extraction ) or biological factors such as obesity
to “ no reportable resultleadingto “ no reportable result
impairment in the electrical performance of the printed structurecausesimpairment in the electrical performance of the printed structure
to lower valueleadsto lower value
shape distortion in densificationcausingshape distortion in densification
primarily from trophoblastoriginatesprimarily from trophoblast
in low xylene extractables 4resultingin low xylene extractables 4
in low xylene extractables Low blooming of amorphous and low Mw ( molecular weight ) fractions and additives , giving stable surface properties Low migration for metallised filmresultingin low xylene extractables Low blooming of amorphous and low Mw ( molecular weight ) fractions and additives , giving stable surface properties Low migration for metallised film
improved sequencing and selected analysis of the most informative sequencesshould resultimproved sequencing and selected analysis of the most informative sequences
in practice - changing phase III trialsresultingin practice - changing phase III trials